YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of 2024, driven by sustained growth in prescriptions for XHANCE® (fluticasone propionate).
“Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth quarter of 2024,” said CEO Ramy Mahmoud. He noted an estimated 20% sequential growth in prescriptions compared to the third quarter, describing it as an encouraging indicator of ongoing commercial success and momentum heading into 2025.
The announced figures are based on preliminary data and subject to change following the completion of financial closing and auditing procedures. Optinose plans to release finalized financial results and provide corporate updates in March.
XHANCE, a prescription nasal spray, is central to Optinose’s commercial portfolio and has shown consistent market growth. Despite the preliminary nature of the report, the company remains optimistic about sustaining its commercial trajectory in the year ahead.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.